Metastatic Lung Cancer Clinical Trial
Official title:
Evaluating Cryoablation of Metastatic Lung/Pleura Tumors in Patients - Safety and Efficacy
ECLIPSE will evaluate the safety and efficacy of cryoablation therapy used to treat tumors less than or equal to 3.5 centimeters (cm) in participants with pulmonary metastatic disease.
ECLIPSE is a treatment, Phase 1 multicenter, prospective, single-arm study with participants serving as their own control. This study is to enroll participants who will undergo cryoablation of at least 1 metastatic pulmonary tumor that is less than or equal to 3.5 cm. Participants will be followed for 5 years post their cryoablation procedure. Cryoablation is the process of destroying tissue by the application of extremely cold temperatures. Galil Medical Cryoablation Systems are used as a surgical tool in the fields of general surgery, dermatology (skin), neurology (nerves), chest surgery (including lung), Ears-Nose-Throat (ENT), gynecology, oncology (cancer), proctology (colon/rectal), and urology (kidney). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Recruiting |
NCT05846594 -
A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer
|
Phase 4 | |
Not yet recruiting |
NCT03514329 -
Vapor Ablation for Localized Cancer Lesions
|
N/A | |
Recruiting |
NCT05502913 -
Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer
|
Phase 2 | |
Recruiting |
NCT06060613 -
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00986661 -
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
|
Phase 1 | |
Recruiting |
NCT05609578 -
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
|
Phase 2 | |
Completed |
NCT01543672 -
Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously
|
Phase 1/Phase 2 | |
Completed |
NCT03198468 -
Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE)
|
N/A | |
Recruiting |
NCT06180460 -
CALM: Managing Distress in Malignant Brain Cancer
|
N/A | |
Completed |
NCT04804137 -
Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study
|
||
Recruiting |
NCT06343402 -
Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT04940325 -
Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05241873 -
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
|
Phase 1/Phase 2 | |
Recruiting |
NCT05256290 -
Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
|
Phase 1/Phase 2 | |
Completed |
NCT05908799 -
Emulation of the KEYNOTE-189 Trial Using Electronic Health Records
|
||
Active, not recruiting |
NCT03867175 -
Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
|
Phase 3 | |
Recruiting |
NCT04708483 -
DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria
|
N/A | |
Recruiting |
NCT03143322 -
Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases
|
N/A | |
Recruiting |
NCT05143970 -
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
|
Phase 1 |